Germany’s Cannabis Act (CanG) has not led to an increase in use among young people, according to new peer-reviewed research adding to the growing body of evidence contradicting the harms predicted by the reform’s critics.
This morning, the latest in a now-weekly series of stories in the British mainstream press was published in The Times, for the second week in a row taking aim at the advertising practices of some of the UK’s largest clinics.
As the excitement around President Donald Trump’s executive order to push forward with cannabis rescheduling has faded, the bill is now facing a much harsher reality.
When Germany introduced the Recreational Cannabis Act (KCanG), it not only legalised home cultivation and consumption for adults but also laid the groundwork for scientifically monitored pilot projects allowing the legal sale of cannabis at authorised distribution points.
Last week, Business of Cannabis reported on the publication of Germany’s first official evaluation of its Recreational Cannabis Act (KCanG) and the early data suggesting limited social and health impacts from legalisation.
Two new bipartisan bills to legalise adult-use cannabis have been introduce by lawmakers in Pennsylvania, reiginiting hopes for advocates and potentially making the state the 25th in the US to push through such legislation.
Today, Cannabis Europa 2025 welcomed hundreds of the world’s leading cannabis voices for its first jam packed day of sessions.
In a press release published on 9 April, the Académie de Médecine (French Academy of Medicine) reiterated its prohibitionist stance on cannabis, citing a select range of public health concerns and international studies to support its position while consciously omitting the harm caused by prohibition.
Cannabis legalization leads to a reduction in the retail sales of beer, according to new data published in the journal of Drug and Alcohol Dependence.
